Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyQualChoice Abaloparatide (Tymlos) Coverage | OpenP…
    Ask Trek AI about this page
    CurrentQualChoicePolicy CP.PCH.61

    Abaloparatide (Tymlos) coverage

    Customize your policy alerts

    Sign up for QualChoice Policy CP.PCH.61 alerts

    Get alerted when Policy CP.PCH.61 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical necessity and prior authorization criteria for abaloparatide (Tymlos) for treatment of osteoporosis in postmenopausal women and men at high fracture risk, and continuation criteria for members under QualChoice lines of business.

    Policy Summary
    PayerQualChoice
    PolicyAbaloparatide (Tymlos) coverage
    Policy CodePolicy CP.PCH.61
    Change TypeNo material change
    Effective DateJun 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization and submit documentation showing member meets all approval criteria, including fracture risk or prior bisphosphonate therapy history.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    80 mcg/daymaximum daily dose
    2 yearslifetime PTH analog limit
    12 moHIM approval duration
    6 moCommercial approval duration
    J3490

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    example coding referenced
    CP.PCH.61policy identifier

    Coverage Criteria

    Initial Therapy

    Covered when ALL of the following are met:

    Initial Osteoporosis Criteria

    • a. Very high fracture risk: Member is at very high risk for fracture as evidenced by (i) recent osteoporotic fracture within the past 12 months OR (ii) BMD T-score at hip or spine ≤ -3.0 OR (iii) BMD T-score at hip or spine ≤ -2.5 AND major osteoporotic fracture (hip, spine, forearm, wrist, humerus).
    • b. Prior bisphosphonate therapy

      • Exceptions to bisphosphonate requirement: (i) All bisphosphonates contraindicated; (ii) Clinically significant adverse effects to both IV and PO formulations; (iii) Loss of BMD while receiving bisphosphonate therapy; (iv) Lack of BMD increase after ≥ 12 months of bisphosphonate therapy; (v) Osteoporotic or fragility fracture while receiving bisphosphonate therapy.
    Other Initial Requirements: 2. Age ≥ 18 years or documentation of closed epiphyses on x-ray; 3. Member has not received ≥ 2 years cumulative abaloparatide therapy; 4. Dose does not exceed both: (a) 80 mcg per day and (b) 1 pen every 30 days.

    Continuation Therapy

    Continued therapy is covered when ALL of the following are met:

    Continued Osteoporosis Criteria: 1. Member meets one of the following: (a) currently receiving medication via Centene benefit or previously met initial approval criteria OR (b) currently receiving medication and enrolled in a state/product with continuity of care regulations; 2. Member is responding positively to therapy; 3. Member has not received ≥ 2 years cumulative abaloparatide therapy; 4. If request is for a dose increase, new dose does not exceed both: (a) 80 mcg per day and (b) 1 pen every 30 days.

    Non‑FDA approved indications that are not specifically addressed in this policy are excluded from coverage unless there is sufficient documentation of efficacy and safety in accordance with the applicable off‑label use policies (see CP.CPA.09 for Commercial, HIM.PA.154 for Health Insurance Marketplace) or an approved evidence of coverage document.

    For members covered by Medicaid, any state Medicaid coverage provisions that conflict with the terms of this clinical policy take precedence. Providers should refer to the applicable state Medicaid manual for specific coverage rules that supersede this policy.

    Use of abaloparatide (Tymlos) for diagnoses or indications that are not FDA‑approved and are not addressed within this policy is not authorized unless appropriate supporting documentation is provided per the applicable off‑label use policy or evidence of coverage.

    Product Coding & Limits

    Product Availability / NDCNDC
    NDC not listedProduct availability: single-patient-use prefilled pen: 3, 120 mcg/1.56 mL (30 daily doses of 80 mcg)
    Referenced HCPCS/NDCHCPCS
    J3490Unclassified drugs
    inv-08: Maximum daily dose — 80 mcg/day.
    Maximum daily dose80 mcg per day
    Policy citationDose limit listed in Initial Approval Criteria and Dosage & Administration (Appendix E)
    ApplicabilityApplies to PMO and male osteoporosis dosing: 80 mcg SC QD
    inv-09: Maximum pens per interval — 1 pen every 30 days.
    Maximum pens per interval1 pen every 30 days
    Policy contextDefined as a concurrent dosing limit in Initial Approval Criteria (dose does not exceed both 80 mcg/day and 1 pen every 30 days)

    Provider Actions & Authorization

    Prior Authorization

    Obtain prior authorization; note approval durations and lifetime limit

    Prior authorization is required for abaloparatide (Tymlos). Approval durations: HIM — 12 months; Commercial — 6 months or to the member's renewal date, whichever is longer. A cumulative lifetime limit of 2 years of abaloparatide use applies.

    • Approval durations: HIM 12 months; Commercial 6 months or to renewal date
    • Cumulative lifetime abaloparatide use limit: 2 years
    Billing Rule

    Document prior authorization for drug billing (e.g., J3490)

    If billing under an unclassified drug code, obtain and document any required prior authorization per Health Plan procedures. J3490 is referenced in this policy as an example HCPCS code for unclassified drugs.

    Background

    Abaloparatide (Tymlos) is a parathyroid hormone‑related peptide analog indicated for the treatment of osteoporosis in postmenopausal women and in men at high risk for fracture. It acts as an anabolic agent to increase bone mineral density and reduce the risk of vertebral and nonvertebral fractures. Product availability is provided as a single‑patient use prefilled pen containing 120 mcg/1.56 mL (30 daily doses of 80 mcg); clinical guidance and guideline references supporting its use are cited in the policy references.

    Definitions & Thresholds

    inv-20: High risk for fracture — e.g., history of osteoporotic fracture or multiple risk factors.
    DefinitionHistory of osteoporotic fracture or multiple risk factors for fracture.
    Policy useUsed to define 'high risk for fracture' for FDA indications and initial approval criteria.
    ExamplesIncludes prior osteoporotic fracture (recent fracture within 12 months) and multiple clinical risk factors considered by clinician.
    inv-21: BMD T-score thresholds — WHO T-score guidance and severe osteoporosis designation.
    WHO T-score guidanceNormal: ≥ -1.0; Osteoporosis: ≤ -2.5
    Severe osteoporosis designationSevere osteoporosis when T-score ≤ -2.5 in the presence of a fragility fracture
    Policy Summary
    PayerQualChoice
    PolicyAbaloparatide (Tymlos) coverage
    Policy CodePolicy CP.PCH.61
    Change TypeNo material change
    Effective DateJun 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization and submit documentation showing member meets all approval criteria, including fracture risk or prior bisphosphonate therapy history.
    SourceLink
    On This Page
    Coverage CriteriaProduct Coding & LimitsProvider Actions & AuthorizationBackgroundDefinitions & Thresholds
    Product unit noteSingle‑patient‑use prefilled pen contains 30 daily doses of 80 mcg (see Product Availability)
    inv-10: Cumulative lifetime PTH analog use — ≤ 2 years.
    Cumulative lifetime PTH analog use≤ 2 years
    Policy placementListed as a criterion for initial and continued therapy (member has not received ≥ 2 years cumulative abaloparatide therapy)
    Dosage guidanceMaximum duration aligns with Dosage & Administration: up to 2 years cumulative PTH analog use lifetime
    • Example code referenced: J3490 (Unclassified drugs)
    • Document prior authorization for drug billing as required by the plan
    Prior Authorization

    Provide documentation that member meets high‑risk or prior bisphosphonate trial requirement

    For initial approval, document that the member either is at very high risk for fracture OR has completed a 3‑year trial of bisphosphonate therapy (generic alendronate preferred) at maximally indicated doses unless an exception applies. Include evidence cited in the criteria (e.g., recent osteoporotic fracture, BMD T-score thresholds, or reasons bisphosphonate therapy is contraindicated or ineffective).

    • Very high fracture risk evidence: recent osteoporotic fracture within 12 months; BMD T‑score ≤ -3.0 at hip or spine; or BMD T‑score ≤ -2.5 plus a major osteoporotic fracture
    • OR: completed a 3‑year trial of bisphosphonate therapy (generic alendronate preferred) unless one of listed exceptions applies
    Step Therapy

    No explicit step therapy beyond listed initial requirements

    No additional step therapy protocols are specified in this policy; the document does not impose a separate step‑therapy sequence beyond the initial criteria requiring either very high fracture risk or prior bisphosphonate therapy.

    • Policy does not define extra step therapy requirements beyond the initial criteria
    Documentation Required

    Submit clinical documentation to support that approval criteria are met

    Providers must submit supporting documentation such as office chart notes, laboratory results, and other clinical information to show the member has met all approval criteria.

    • Examples of acceptable documentation: office chart notes, lab results, other clinical information
    Documentation Required

    Align documentation and claims with the clinical policy and member coverage terms

    Use this clinical policy as a guide to medical necessity, and ensure claims and coverage decisions follow all terms, conditions, exclusions, and limitations of the member's coverage documents and applicable law.

    • Verify member's coverage documents (e.g., evidence of coverage, certificate of coverage) and applicable law when submitting claims
    Denial Risk

    Non‑FDA use may be denied without off‑label or evidence support

    Requests for non‑FDA approved indications that are not addressed in this policy may be denied unless there is sufficient documentation of efficacy and safety per the applicable off‑label use policies (CP.CPA.09, HIM.PA.154) or evidence of coverage.

    • Non‑FDA indications require supporting documentation per Off‑Label Use policies: CP.CPA.09 (Commercial) or HIM.PA.154 (Health Insurance Marketplace)
    Note

    Coding listed in policy does not guarantee coverage or payment

    Inclusion or exclusion of codes in this policy does not guarantee payment. Providers should reference the most up‑to‑date professional coding guidance prior to claim submission.

    • Codes listed are informational only; verify current coding guidance before billing
    • Coding presence in policy does not ensure coverage or payment
    Policy thresholdsInitial criteria reference BMD T-score thresholds (e.g., ≤ -3.0 at hip or spine as evidence of very high fracture risk)
    inv-22: Osteoporosis management references — Guideline and position statement citations for diagnosis, fracture risk assessment, and pharmacologic therapy.
    Endocrine Society guidelineShoback D, Rosen CJ, Black DM, et al. Pharmacological management of osteoporosis — J Clin Endocrinol Metab. 2020.
    AACE/ACE guidelineCamacho PM, Petak SM, Brinkley N, et al. AACE/ACE clinical practice guidelines for diagnosis and treatment of postmenopausal osteoporosis — Endocr Pract. 2020.
    National Bone Health Alliance positionSiris ES, Adler R, Bilezikian J, et al. Clinical diagnosis of osteoporosis: position statement — Osteoporos Int. 2014.
    Additional referencesLeBoff MS, Greenspan SL, et al. Clinician's guide to prevention and treatment of osteoporosis — Osteoporos Int. 2022; Qaseem A, et al. ACP living guideline 2024.